KNG1 and angioedema: The absence of any change in the frequency of angioedema after discontinuation of ACEI, despite the change to another antihypertensive therapeutic class in this series, casts doubt on the actual bradykinin mechanism of AE in these patients, especially as the half-life of ACEI does not explain the persistence of bradykinin induced AE attacks 6 months after discontinuation.13